Vivani Medical, INC 8-K filings

Vivani Medical's GLP-1 implant demonstrated an 82% reduction in liver fat in preclinical studies, with clinical trials for their obesity program expected to begin in the fourth quarter of 2024.

Vivani Medical announced progress in its GLP-1 implant programs, including the expected initiation of a first-in-human study for its obesity implant in Q4 2024, and reported its second quarter 2024 financial results.

Vivani Medical plans to begin its first clinical trial for its 6-month GLP-1 implant for obesity treatment in the fourth quarter of 2024.

Vivani Medical's 2024 Annual Meeting saw the election of six directors, ratification of the auditor, and an advisory vote on executive compensation.

Vivani Medical has announced that the FDA has lifted the clinical hold on its NPM-119 drug implant, allowing the company to begin its Phase 1 clinical trial.

Vivani Medical announced positive preclinical data for its NPM-115 weight loss implant, comparable to semaglutide, and reported its first quarter 2024 financial results, highlighting a stable financial position.

Vivani Medical has entered into an agreement with Jefferies LLC to potentially sell up to $75 million of its common stock through an at-the-market offering.

Vivani Medical shifts strategic focus to obesity treatment, reports positive preclinical data for its GLP-1 implant, and secures $15 million in funding to accelerate development programs.

Vivani Medical appoints Daniel Bradbury, former CEO of Amylin Pharmaceuticals, to its Board of Directors as they focus on developing GLP-1 implants.

Vivani Medical has announced a $15 million registered direct offering of common stock and warrants to an institutional investor.

Vivani Medical reports positive preclinical results for its NPM-115 exenatide implant, showing weight loss comparable to Ozempic/Wegovy, and discloses NPM-139 as a semaglutide implant, shifting its focus to obesity treatments.